<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581187</url>
  </required_header>
  <id_info>
    <org_study_id>GIMEMA-ALLIANCE Platform</org_study_id>
    <nct_id>NCT04581187</nct_id>
  </id_info>
  <brief_title>An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies</brief_title>
  <official_title>An onLine-pLatform to Improve Patient-centered Care During the COVID-19 pAndemic: a GIMEMA surveillaNce Program in hematologiC malignanciEs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national multicenter prospective observational study led by the GIMEMA. The&#xD;
      GIMEMA-ALLIANCE Platform is also an online monitoring system for patients with hematologic&#xD;
      malignancies aiming at helping hematologists in the early recognition and timely management&#xD;
      of problems of their patients. Based on patient's rating of specific items (i.e. on the&#xD;
      presence of clinically relevant problems or problems with adherence to therapy or risk of&#xD;
      SARS-CoV-2 infection), the Platform will automatically send alerts to the treating&#xD;
      hematologist (and/or appointed members of the local Team). Physicians will be free to make&#xD;
      any action they feel appropriate for the best care of their patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>HRQOL in adult patients with hematologic malignancies</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To prospectively assess HRQOL in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms in adult patients with hematologic malignancies</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To prospectively assess symptoms in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to therapy in adult patients with hematologic malignancies</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To prospectively assess adherence to therapy in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of clinically relevant functional limitations and symptoms</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To describe the prevalence of clinically relevant functional limitations (e.g., physical and social) and symptoms (e.g., fatigue, pain and dyspnea) by type of hematologic malignancy and by type of treatment (e.g., standard chemotherapy of oral anticancer therapies)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with physical and mental health concerns, as measured by EORTC QLQ-C30 questionnaire</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To investigate factors associated with physical and mental health concerns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Financial and social impact imposed by the COVID-19 pandemic on patient health outcomes</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To examine the financial and social impact imposed by the COVID-19 pandemic on patient health outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To examine the limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical strategies adopted by physicians</measure>
    <time_frame>After 2 years from date of registration</time_frame>
    <description>To describe clinical strategies adopted by physicians in response to patient-generated alerts, across different clinical scenarios</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life assessment</intervention_name>
    <description>Quality of life questionnaires</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with any hematologic malignancy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any hematologic malignancy according to 2016 WHO classification&#xD;
&#xD;
          -  Adult Patients (≥18 years).&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major cognitive deficits or psychiatric problems hampering a self-reported evaluation.&#xD;
&#xD;
          -  Not able to read and understand local language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Vignetti</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Efficace</last_name>
    <phone>+39 06441639831</phone>
    <email>alliance@gimema.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti &quot;Umberto I - G.M. Lancisi - G. Salesi&quot;- Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico Di Aviano - Sosd Oncoematologia Trapianti Emopoietici E Terapie Cellulari</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Oncologico Istituto Tumori Giovanni Paolo II - UO Ematologia</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asl Della Provincia Di Barletta, Andria, Trani, Ospedale &quot;Mons. Dimiccoli&quot; - UOC Ematologia</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Brotzu, Presidio Ospedaliero A. Businco - Cagliari - SC Ematologia E CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico Vittorio Emanuele, Presidio Ospedaliero Ferrarotto -Divisione Clinicizzata Di Ematologia</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti - Foggia- UOC Ematologia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Di Modena- Sc Ematologia- Dipartimento Di Oncologia Ed Ematologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ao Di Rilievo Nazionale Antonio Cardarelli - UOC Ematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Aou Maggiore Della Carità Di Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico P. Giaccone - Uo Ematologia Dipartimento Biomedico Di Medicina Interna E Specialistica</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ausl Reggio Emilia, Presidio Ospedaliero &quot;Arcispedale Santa Maria Nuova&quot; - Irccs- Uo Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ao San Camillo Forlanini - Uoc Ematologia E Trapianto Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Tor Vergata - UOC Trapianto Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico Umberto I - Dipartimento Di Medicina Traslazionale - Sezione Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio Medico - Roma - Uoc Ematologia E Trapianto Di Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aou Di Sassari - Cliniche Universitarie - Stabilimento Cliniche Di San Pietro - Uoc Ematologia</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Sassuolo Spa - Ematologia</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asl To 2, Torino Nord Emergenza San Giovanni Bosco - Ssd Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Torino Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

